In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

COPD, a progressive condition affecting millions globally, has historically relied on inhaled therapies ... Unmet Needs and Drug Forecast to 2033 report. The upcoming Phase III data for Fasenra ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

LOS ANGELES -- For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ...

The drug didn’t show any superiority in the ... Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.

In addition to the asthma and COPD program, Transpire Bio is developing therapies for other diseases with significant unmet needs. These efforts leverage the company's proprietary drug delivery ...

Cholinergic drugs (acetylcholine ... asthmatics and in COPD patients with a history of asthma, showing an additional bronchodilator effect on top of the current asthma treatment.

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...